Designer Benzodiazepines Gidazepam and Desalkygidazepam (Bromonordiazepam): What Do We Know?

J Anal Toxicol

School of Nursing and Healthcare Leadership, University of Bradford, Bradford BD7 1DB, UK.

Published: April 2023

Designer benzodiazepines are one of the primary new psychoactive substance (NPS) threats around the world, being found in large numbers in postmortem, driving under the influence of drugs and drug-facilitated sexual assault cases. Even though when compared to many other NPS types, such as opioids and cathinones, there are relatively few designer benzodiazepines being monitored. Recently, a new NPS benzodiazepine has been reported in Europe, the USA and Canada, desalkygidazepam, also known as bromonordiazepam. This substance is a metabolite of the prodrug gidazepam, a drug licensed for use in Ukraine and Russia under the name Gidazepam IC®. In the paper, we review what is currently known about the use, pharmacology and analytical detection of gidazepam, its metabolite desalkygidazepam and their other possible metabolites.

Download full-text PDF

Source
http://dx.doi.org/10.1093/jat/bkad004DOI Listing

Publication Analysis

Top Keywords

designer benzodiazepines
12
desalkygidazepam bromonordiazepam
8
gidazepam
4
benzodiazepines gidazepam
4
gidazepam desalkygidazepam
4
bromonordiazepam know?
4
know? designer
4
benzodiazepines primary
4
primary psychoactive
4
psychoactive substance
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!